Core Insights - The company has made strategic advancements in the field of neuroscience, focusing on neurodegenerative diseases such as Alzheimer's and Parkinson's, in response to China's aging population [1] Company Developments - The company has introduced advanced early screening technologies and aims to create a comprehensive product line that includes early risk screening, precise diagnosis, and brain health management [1] - In the neuroimmunology sector, the company is leveraging its proprietary database to develop cost-effective antibody testing combinations to meet the personalized monitoring needs for various neuroimmunological diseases and new immunotherapy treatments [1] Financial Performance - For the period from January to September 2025, the company reported revenues of 7.566 billion yuan, representing an 18.28% year-on-year decline [1] - The net profit attributable to the parent company was 57 million yuan, reflecting a significant year-on-year decrease of 56.67% [1]